Expert Reviews in Hematology 2014: Highlights from the Annual Hematology Meeting

After successfully completing this continuing medical education activity, participants should be able to:

-->Summarize new insights into the biology of hematologic malignancies, benign hematologic disorders, and explain how these findings are being used to develop new and improved treatment strategies
-->Review the latest clinical trial updates on new and emerging therapies for hematologic malignancies and benign hematologic disorders, and discuss issues in incorporating these agents into clinical practice
-->Incorporate novel tools and strategies for diagnosis, prognosis, and risk stratification into management of hematologic malignancies and benign hematologic disorders
-->Consider various patient subgroups (younger, elderly, newly diagnosed, relapsed, treatment-refractory, etc.) when formulating treatment algorithms for patients with hematologic malignancies and benign hematologic disorders
-->Discuss major findings and expert perspectives presented at ASH 2013 and their potential impact on current clinical guidelines and standards of care